Two GALVmed facilitated Porcine Cysticercosis products, a registered therapeutic (oxfendazole) and an unregistered vaccine (TSOL 18) have recently commenced field trials to evaluate their joint potential as a public health tool in the control of human neurocysticercosis (treating and vaccinating pigs breaks the parasitic cycle responsible for neurocysticercosis). This work therefore represents an atypical strand of GALVmed strategy in that increased agricultural productivity is a secondary consideration after improved human health. The broad objectives for the period are:
GALVmed realises the threat to the livelihoods of small-scale pig owners imposed by ASF. Control tools for ASF do not currently exist in the market. Therefore GALVmed has worked with a UK research institute to provide an attractive package for commercialisation that comprises access to a prototype vaccine candidate and a permissive continuous cell line for viral growth. This limited project is nearing the stage of commercial partner selection if further data look promising.